$OKLO

Oklo reports $1.21M Q2 revenue, $1.6B cash as Aurora milestones advance

Oklo Inc. (NYSE: OKLO) reported Q2 2026 revenue of $1.21M versus a $126,250 analyst estimate and an EPS loss of $(0.28) versus an estimated $(0.16). The company said it ended the quarter with $1.6B cash and expects 2026 operating cash flow of $120M to $150M and capex of $400M to $500M. It also advanced Aurora regulatory steps and said its Groves reactor reached first criticality.

Original reporting
Published Aug 7, 2026, 6:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 12:38 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oklo reports $1.21M Q2 revenue, $1.6B cash as Aurora milestones advance — source image
Decision brief

The 30-second read

$OKLONeutralMed
01

Why it matters

The article combines a first-ever quarterly revenue print with balance-sheet runway and specific DOE regulatory steps (site use permit, HALEU fuel allocation, and safety documents), plus customer pipeline updates and a separate operational milestone (Groves first criticality).

02

Market read

Traders get a fresh earnings-style datapoint (revenue and EPS loss) alongside tangible regulatory and fuel-allocation progress for Aurora, which can shift near-term expectations for commercialization timing.

03

What to watch

Investors may focus less on prototype milestones (criticality) and more on whether Aurora commercialization can convert DOE allocations and LOIs into binding contracts and recurring cash flow.

Relevance 8/10Novelty 7/10Timing: post-market/next-session reaction after Aug 7 Q2 results and Aurora milestone updates

Background

Oklo is an advanced nuclear company targeting deployment of its first Aurora powerhouse by 2028, while also advancing its Groves isotope test reactor under the DOE Reactor Pilot Program.

Company-level read

Ticker impact

$OKLONeutralMedium confidence
Context

Oklo reported Q2 2026 revenue of $1.21M, ended with $1.6B cash, and advanced Aurora milestones including DOE site use permit and HALEU allocation.

Expected impact

Choppy to mildly positive bias, with upside capped by continued cash burn and capital intensity.

Evidence & confidence

The article provides fresh, decision-relevant datapoints (Q2 results plus DOE permit and fuel allocation) but also highlights a widening loss and heavy capex, which can limit multiple expansion.

Market effects

Reinforces that advanced nuclear developers can progress through DOE pathways while still reporting losses, keeping sector valuation sensitive to cash runway.

Limited direct regional impact; Idaho National Laboratory and Ohio power campus are US-specific execution milestones.

Modest, as the story is primarily US regulatory and customer pipeline progress rather than global policy shifts.

Counterpoint

The revenue beat may reflect timing or non-recurring project activity, while the widening EPS loss and large capex range suggest dilution or financing risk remains the real driver.

Key entities

  • Oklo Inc.

    Reported Q2 2026 revenue and loss, highlighted $1.6B cash, and detailed Aurora regulatory progress and customer pipeline.

  • U.S. Department of Energy (DOE)

    Provided the site use permit and HALEU fuel allocation framework and receives safety documents for Aurora regulatory pathway.

  • Idaho National Laboratory (INL)

    The Aurora Idaho location tied to the DOE site use permit and HALEU allocation.

  • Meta

    Entered a prepayment agreement with Oklo for a 1.2 GW power campus in Ohio for Meta data centers.

Related articles

$OKLOMed

Oklo Inc. Q2 2026 Earnings Call Summary

Oklo Inc. reported progress from its Q2 2026 earnings call, including first criticality at the Groves isotope facility and plans for Aurora deployments at INL and an Ohio clean energy campus. The company targeted 2028 commercial startup, expected first isotope revenue in early 2027, and raised 2026 operating cash use guidance to $120M-$150M and PP&E spend to $400M-$500M.

$OKLOMed

Oklo Stock Attempts a Turnaround, but Technical Barriers Remain as It Releases Q2 2026 Financial Results

Oklo reported Q2 2026 revenue of $1.2 million, above analysts’ ~$83,800 estimate, but posted a $0.28 per-share loss versus a ~$0.16 consensus. Net loss widened to $48.5 million from $24.7 million a year earlier. The company ended the quarter with about $3 billion in cash and marketable securities and said its Groves Isotope Test Reactor achieved first criticality.

$OKLOMed

Oklo's Groves Reactor Just Achieved First Criticality. Here's What It Means for OKLO Stock.

Oklo said its Groves Isotope Test Reactor in Texas achieved first criticality on Aug. 5, marking the first self-sustaining fission chain reaction at the Groves site, according to the company. Oklo noted it was the first DOE Reactor Pilot Program project to reach criticality from a greenfield private-land site. The firm reiterated targets for Aurora-INL late 2027 to early 2028 and Aurora-Ohio startup in early 2030.

$OKLOMedAI 8/10

OKLO Q2 FY2026 earnings call — BigGo Finance

Oklo Inc. reported a first-half 2026 net loss of $81.6 million, with operating loss of $124.2 million offset by $44.5 million of net interest and dividend income, and no revenue recognized. Cash and marketable securities were $3.0 billion at June 30, 2026. Management raised FY2026 operating cash use to $120 million-$150 million and capex to $400 million-$500 million. Key updates include Groves first criticality and DOE progress for Aurora-INL.